Q3 Earnings Estimate for 908 Devices Issued By William Blair

908 Devices Inc. (NASDAQ:MASS - Free Report) - Equities research analysts at William Blair raised their Q3 2025 EPS estimates for 908 Devices in a report issued on Monday, May 19th. William Blair analyst M. Larew now expects that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.09). The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices' Q4 2025 earnings at ($0.02) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.09) EPS.

908 Devices (NASDAQ:MASS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. The company had revenue of $11.78 million during the quarter, compared to analysts' expectations of $11.90 million. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 908 Devices in a report on Saturday, May 10th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $5.33.

908 Devices Stock Performance

NASDAQ MASS traded up $0.06 during trading hours on Wednesday, reaching $4.80. The stock had a trading volume of 279,729 shares, compared to its average volume of 999,019. 908 Devices has a 52-week low of $1.81 and a 52-week high of $6.72. The stock has a fifty day moving average of $4.64 and a 200 day moving average of $3.31. The stock has a market cap of $172.13 million, a P/E ratio of -2.71 and a beta of 0.26.

Insider Buying and Selling at 908 Devices

In other 908 Devices news, Director Mark Spoto bought 10,000 shares of 908 Devices stock in a transaction on Wednesday, May 14th. The shares were bought at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the acquisition, the director now directly owns 62,971 shares in the company, valued at $270,145.59. This represents a 18.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 27.70% of the stock is currently owned by corporate insiders.

Institutional Trading of 908 Devices

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its position in 908 Devices by 4.0% in the first quarter. Bank of New York Mellon Corp now owns 51,915 shares of the company's stock valued at $233,000 after acquiring an additional 1,985 shares during the last quarter. American Century Companies Inc. lifted its stake in 908 Devices by 10.8% in the first quarter. American Century Companies Inc. now owns 45,814 shares of the company's stock valued at $205,000 after buying an additional 4,471 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in shares of 908 Devices by 32.2% in the fourth quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after acquiring an additional 5,112 shares during the period. CWM LLC increased its holdings in shares of 908 Devices by 541.2% in the 1st quarter. CWM LLC now owns 6,963 shares of the company's stock valued at $31,000 after acquiring an additional 5,877 shares during the period. Finally, LPL Financial LLC raised its position in 908 Devices by 13.0% in the 4th quarter. LPL Financial LLC now owns 63,287 shares of the company's stock valued at $139,000 after purchasing an additional 7,295 shares during the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.